KR100308491B1 - Composition for growthing hair - Google Patents
Composition for growthing hair Download PDFInfo
- Publication number
- KR100308491B1 KR100308491B1 KR1019990029648A KR19990029648A KR100308491B1 KR 100308491 B1 KR100308491 B1 KR 100308491B1 KR 1019990029648 A KR1019990029648 A KR 1019990029648A KR 19990029648 A KR19990029648 A KR 19990029648A KR 100308491 B1 KR100308491 B1 KR 100308491B1
- Authority
- KR
- South Korea
- Prior art keywords
- vitamin
- hair
- composition
- extract
- hair growth
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 210000004209 hair Anatomy 0.000 title abstract description 36
- 239000000284 extract Substances 0.000 claims abstract description 52
- 230000003779 hair growth Effects 0.000 claims abstract description 45
- 229940088594 vitamin Drugs 0.000 claims abstract description 36
- 229930003231 vitamin Natural products 0.000 claims abstract description 36
- 235000013343 vitamin Nutrition 0.000 claims abstract description 36
- 239000011782 vitamin Substances 0.000 claims abstract description 36
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 31
- 235000003434 Sesamum indicum Nutrition 0.000 claims abstract description 29
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims abstract description 23
- 229960001727 tretinoin Drugs 0.000 claims abstract description 23
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 15
- 239000002243 precursor Substances 0.000 claims abstract description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 14
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims abstract description 12
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 12
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 12
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960002477 riboflavin Drugs 0.000 claims abstract description 12
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000020710 ginseng extract Nutrition 0.000 claims abstract description 11
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims abstract description 9
- 235000011613 Pinus brutia Nutrition 0.000 claims abstract description 9
- 241000018646 Pinus brutia Species 0.000 claims abstract description 9
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 9
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 9
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 9
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 8
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 8
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 7
- 229960002685 biotin Drugs 0.000 claims abstract description 7
- 235000020958 biotin Nutrition 0.000 claims abstract description 7
- 239000011616 biotin Substances 0.000 claims abstract description 7
- 229960003495 thiamine Drugs 0.000 claims abstract description 7
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 7
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 7
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 7
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims abstract description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 6
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 6
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 6
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 6
- 229940055726 pantothenic acid Drugs 0.000 claims abstract description 6
- 235000019161 pantothenic acid Nutrition 0.000 claims abstract description 6
- 239000011713 pantothenic acid Substances 0.000 claims abstract description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 6
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 6
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 6
- 239000011718 vitamin C Substances 0.000 claims abstract description 6
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 6
- 239000011709 vitamin E Substances 0.000 claims abstract description 6
- 229940046009 vitamin E Drugs 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 4
- 229960000304 folic acid Drugs 0.000 claims abstract description 4
- 235000019152 folic acid Nutrition 0.000 claims abstract description 4
- 239000011724 folic acid Substances 0.000 claims abstract description 4
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 4
- 239000011710 vitamin D Substances 0.000 claims abstract description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 4
- 229940046008 vitamin d Drugs 0.000 claims abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- 241000207961 Sesamum Species 0.000 claims description 28
- 238000009472 formulation Methods 0.000 claims description 14
- 239000006071 cream Substances 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims 8
- 239000000686 essence Substances 0.000 claims 1
- 239000000419 plant extract Substances 0.000 abstract description 17
- 230000004060 metabolic process Effects 0.000 abstract description 14
- 238000011282 treatment Methods 0.000 abstract description 11
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract description 8
- 102000004190 Enzymes Human genes 0.000 abstract description 5
- 108090000790 Enzymes Proteins 0.000 abstract description 5
- 210000000981 epithelium Anatomy 0.000 abstract description 4
- 229930002330 retinoic acid Natural products 0.000 abstract description 4
- 229960003604 testosterone Drugs 0.000 abstract description 4
- 230000008929 regeneration Effects 0.000 abstract description 3
- 238000011069 regeneration method Methods 0.000 abstract description 3
- 244000000231 Sesamum indicum Species 0.000 abstract 1
- 201000004384 Alopecia Diseases 0.000 description 65
- 230000003676 hair loss Effects 0.000 description 46
- 208000024963 hair loss Diseases 0.000 description 45
- 231100000360 alopecia Toxicity 0.000 description 12
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 210000003780 hair follicle Anatomy 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 229940088597 hormone Drugs 0.000 description 8
- 239000005556 hormone Substances 0.000 description 8
- 206010068168 androgenetic alopecia Diseases 0.000 description 7
- 201000002996 androgenic alopecia Diseases 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 6
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000003659 hair regrowth Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 6
- 210000004761 scalp Anatomy 0.000 description 6
- 235000019155 vitamin A Nutrition 0.000 description 6
- 239000011719 vitamin A Substances 0.000 description 6
- 229940045997 vitamin a Drugs 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- -1 trisodium citrate cetylisooctanate glycerol 2-ethylhexanoate Chemical compound 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 208000004631 alopecia areata Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 229910052748 manganese Inorganic materials 0.000 description 3
- 239000011572 manganese Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000019192 riboflavin Nutrition 0.000 description 3
- 239000002151 riboflavin Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229940124558 contraceptive agent Drugs 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229960002389 glycol salicylate Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N hydroxymethyl benzene Natural products OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 2
- 208000003532 hypothyroidism Diseases 0.000 description 2
- 230000002989 hypothyroidism Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229940117382 propecia Drugs 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 2
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- ZIBRXDXDSFZIDB-UHFFFAOYSA-N 2,3-dihydroxypropyl octadecanoate propan-2-yl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C.CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO ZIBRXDXDSFZIDB-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- HRLBAVXVBJVWRE-UFLZEWODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 HRLBAVXVBJVWRE-UFLZEWODSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 241000594592 Lanugo Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000008425 Protein deficiency Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HFXAPEDTJDFEHF-UHFFFAOYSA-M [OH-].[K+].CC(O)CO.OCC(O)CO Chemical compound [OH-].[K+].CC(O)CO.OCC(O)CO HFXAPEDTJDFEHF-UHFFFAOYSA-M 0.000 description 1
- IZQZNLBFNMTRMF-UHFFFAOYSA-N acetic acid;phosphoric acid Chemical compound CC(O)=O.OP(O)(O)=O IZQZNLBFNMTRMF-UHFFFAOYSA-N 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- MSGANTLREPLCQN-UHFFFAOYSA-N ethanol;propane-1,2-diol;propane-1,2,3-triol Chemical compound CCO.CC(O)CO.OCC(O)CO MSGANTLREPLCQN-UHFFFAOYSA-N 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000003648 hair appearance Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 229940105902 mint extract Drugs 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N n-butyl para-hydroxybenzoate Natural products CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- PEBOEPBLUCMCGU-UHFFFAOYSA-M sodium 2-[bis(2-hydroxyethyl)amino]ethanol 2-hydroxypropanoate propane-1,2-diol propane-1,2,3-triol Chemical compound [Na+].CC(O)CO.CC(O)C([O-])=O.OCC(O)CO.OCCN(CCO)CCO PEBOEPBLUCMCGU-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 210000004906 toe nail Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 150000003697 vitamin B6 derivatives Chemical class 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 모발 성장 조성물에 관한 것으로, 특히 식물 추출물 및 비타민을 유효성분으로 하는 모발 성장 조성물에 관한 것이다.The present invention relates to a hair growth composition, and more particularly, to a hair growth composition comprising plant extracts and vitamins as an active ingredient.
본 발명은 a) 참깨꽃 추출물; 및 b) 트레티노인(레티노익 산)을 유효 성분으로 하는 모발 성장 조성물을 제공한다. 상기 조성물은 c) 비타민 B1, 비타민 B2, 비타민 B6, 비타민 C, 비타민 D, 비타민 E, 니코틴산, 판토텐산, 비오틴, 및 엽산으로 이루어진 군으로부터 1 종 이상 선택되는 비타민 또는 비타민 전구체를 더 포함할 수 있으며, d) 솔잎 추출물 및 인삼 추출물로 이루어진 군으로부터 1 종 이상 선택되는 추출물도 더욱 포함할 수 있다.The present invention a) sesame flower extract; And b) a hair growth composition comprising tretinoin (retinoic acid) as an active ingredient. The composition may further comprise c) a vitamin or vitamin precursor selected from the group consisting of vitamin B1, vitamin B2, vitamin B6, vitamin C, vitamin D, vitamin E, nicotinic acid, pantothenic acid, biotin, and folic acid; , d) pine needle extract and ginseng extract may further comprise at least one extract selected from the group consisting of.
본 발명의 조성물은 체내의 5-환원 효소를 억제하여 남성 호르몬의 대사 과정에서 DHT가 형성되지 않도록 하고, 인체의 상피조직의 기능 수행에 있어서 세포 재생으로 머리카락의 신진 대사 작용을 도와주도록 하여 남성형 탈모증 치료에 사용될 수 있는 모발 성장 조성물이다.The composition of the present invention inhibits 5-reducing enzymes in the body so that DHT is not formed in the metabolic process of testosterone and helps the hair metabolism by cell regeneration in the functioning of epithelial tissues of the human body. Hair growth compositions that can be used for treatment.
Description
[산업상 이용분야][Industrial use]
본 발명은 모발 성장 조성물에 관한 것으로, 특히 식물 추출물 및 비타민을 유효성분으로 하는 모발 성장 조성물에 관한 것이다.The present invention relates to a hair growth composition, and more particularly, to a hair growth composition comprising plant extracts and vitamins as an active ingredient.
[종래 기술][Prior art]
인간의 모발은 '케라틴'이라는 단백질로 구성되는데, 이 단백질은 손톱이나 발톱을 구성하는 단백질이다. 우리 눈에 보이는 모발은 피부 약 4 mm 아래 자루 모양의 '모낭'에서 형성하는 조직으로 3 층으로 구성된다. 맨 겉층은 얇고 딱딱한 비늘모양의 보호층으로 색체를 띄지 않는다. 중간층은 가장 두껍고 모발을 지탱하는 구조로 직모 또는 꼽슬 여부 그리고 모발의 색을 결정하는 층이다. 제일 안쪽 층은 살아있는 세포들이 구성하는 층으로 모발 성장에 영양공급을 하는 층이다.Human hair consists of a protein called keratin, which is the protein that makes up nails and toenails. Our visible hair consists of three layers of tissue that form from a `` hair follicle '' shaped like a bag about 4 mm below the skin. The outermost layer is a thin, hard, scaly protective layer that does not show color. The middle layer is the thickest, hair-bearing structure that determines whether the hair is straight or humped, and the color of the hair. The innermost layer is the layer of living cells that nourish hair growth.
모낭에는 유두가 있는데, 이 부위에는 작은 혈관이 분포되어 모발성장에 필요한 영양분을 공급하며, 유두 위의 옆으로는 모발에 윤기를 주는 기름을 공급하는 지루샘이 있다. 이와같은 모낭의 성장은 '남성호르몬(testosterone)'의 영향력 밑에 있는데, 겨드랑이와 음부의 모발들이 이 호르몬에 특히 민감하여 다른 신체 부위 모발보다 사춘기 시기에 제일 먼저 나타나고 자란다. 반면에 머리의 모발은 남성호르몬의 유도체인 '디하이드로테스테론(dihydrotestosterone; 이하 DHT)'의 영향을 받는다.There is a papilla in the hair follicle, where small blood vessels are distributed to provide the nutrients needed for hair growth, and the side of the teat has a seborrheic gland that provides shine to the hair. This growth of hair follicles is under the influence of 'testosterone', where the hairs of the armpits and the genitals are particularly sensitive to the hormone and appear first in puberty than other body hair. On the other hand, the hair of the head is affected by 'dihydrotestosterone (DHT)', a derivative of male hormone.
모낭은 원천적으로 태아기에 형성되어 출산 후에는 새로운 모낭이 생성되지 않으며 어른이 되서도 숫자는 똑같이 유지되나 노년기에는 감소한다. 태아 시기에 처음 나타나는 모발은 취모(lanugo hair)라고 하는데 모체 자궁내에서 약 8 개월 중에 떨어져 나간다. 출생 후 나오는 것은 연모(vellus hair)로 가늘고, 연하고, 무색이며 2 cm 이내 크기이다. 이러한 연모는 남성형 탈모증이 진행될 때 앞쪽 머리에서도 볼 수 있다. 사춘기를 거치면서 연모는 성모(terminal hair)로 바뀌어 두껍고, 힘이 있고, 색을 갖는 모발로 바뀐다.Hair follicles are originally formed in the prenatal period, and no new hair follicles are formed after childbirth. The numbers remain the same even in adults, but decrease in later life. The first hair to appear during fetal periods is called lanugo hair, which falls off in the mother's womb in about eight months. After birth is vellus hair, thin, light, colorless and within 2 cm in size. This hair can also be seen in the anterior head when androgenetic alopecia progresses. During puberty, cilia are transformed into terminal hair, turning into thick, strong, colored hair.
이러한 성모의 성장은 남성 호르몬의 영향을 받는데, 남성형 탈모증의 경우 DHT의 영향으로 성모가 연모로 변하면서 궁극적으로 탈모가 되는 현상이 일어난다. 머리에는 보통 평균적으로 100,000개의 성모가 있으며, 이들은 성장기, 퇴행기, 휴지기의 주기적 변화를 하면서 생성, 소멸을 반복한다.The growth of the Virgin is influenced by male hormones. In the case of male alopecia, DHT affects the formation of soft hair and eventually causes hair loss. The head usually has an average of 100,000 virgins, which repeat their creation and disappearance with periodic changes in growth, degeneration, and resting phases.
또한 모발은 나이, 계절, 인종, 생리적인 요인, 스트레스, 질환 등의 여러 요인의 영향을 받으며 하루에 보통 50∼100 개 정도의 정상적인 '퇴행기 탈모'가 일어난다. 보통 모발의 성장기는 약 2∼6 년까지이며 이 시기에 성장이 지속적으로 일어나는데, 성장 속도는 한달에 4∼6 mm 정도이다. 성장속도는 더울 때 가장 빠르며 추울 때 가장 늦다. 그리고 탈모는 봄, 여름 보다 가을, 겨울에 더 많이 일어난다. 모발의 성장은 보통 15 세 에서 30 세 사이에서 가장 활발하며 40, 50 세에 가서 점진적으로 퇴보한다. 나이 50 세 이상이 되면 노화에 의한 자연스런 탈모가 일어나기 시작하여 70 세 이후부터 탈모가 빨라진다.In addition, hair is affected by various factors such as age, season, race, physiological factors, stress, and disease, and usually 50-100 normal 'degenerative hair loss' occurs every day. Normal hair growth is about 2 to 6 years and growth continues at this time, with growth rates of 4 to 6 mm per month. The growth rate is fastest when it is hot and late when it is cold. Hair loss occurs more frequently in autumn and winter than in spring and summer. Hair growth is usually most active between the ages of 15 and 30, and gradually degenerates at age 40 and 50. After age 50, natural hair loss begins to occur due to aging, and hair loss accelerates after 70 years.
한편 탈모의 종류, 원인 및 치료를 살펴보면 다음과 같다.Meanwhile, the types, causes and treatment of hair loss are as follows.
보통 탈모증상을 호소하는 경우를 보면 대부분 주관적이고 관념적이다. 물론 명백한 탈모증세 및 병변이 있는 경우도 있지만 명백한 병변이 없고 객관적으로 탈모 모발 수를 세어보거나 모발모양을 관찰하지 않으며 증세를 호소하는 경우가 많다. 즉 '머리수가 줄었어요'라는 증세를 보면 모발이 가늘어져 있거나 작아진 경우 또는 쉽게 부러지고 끊어지는 현상을 이야기 할 때도 있는데 이때는 모발 수에는 변화가 없는 경우도 많다. 그러므로 탈모증세가 있을 때는 현재 모발 상태를 정확하게 진찰 평가하고, 신체적, 정신적 건강 상태를 전반적으로 파악하는 것이 중요하다.The most common complaints of alopecia are subjective and conceptual. Of course, there are cases of obvious hair loss and lesions, but there are no obvious lesions, and the number of complaints is not counted objectively or the appearance of hair is observed without complaints. In other words, the number of hair is reduced, the hair is thinner or smaller, or sometimes breaks easily and breaks, which is often the case. Therefore, when you have hair loss, it is important to accurately assess your current hair condition and to understand your physical and mental health in general.
이러한 탈모 증세는 원형 탈모증, 휴지기 탈모증, 성장기 탈모증, 두피 질환 및 남성형 탈모증으로 구분되며, 이들을 살펴보면 다음과 같다.These alopecia are classified into alopecia areata, resting alopecia, growing alopecia, scalp disease and androgenetic alopecia, looking at them as follows.
원형 탈모증은 보통 원형모양의 탈모가 1∼2 개씩 갑자기 두피에 발생한다. 두피 이외에도 수염, 눈썹, 음모 등에서도 볼 수 있으며 심한 경우 온몸에서 탈모가 일어날 수 있다. 아직 확실한 원인은 밝혀져 있지는 않지만 자가면역기전으로 일어난다고 생각되며 여기에 유전적, 정신적인(특히 스트레스)소인이 영향을 미친다고 생각한다. 자연적으로 치유되기도 하지만 증상이 3 개월이상 지속되거나 더 진행된다면 치료하는 것이 좋다. 치료는 부신 피질 호르몬제의 병변내 주사와 면역 반응 유발치료가 가장 많이 이용된다.Alopecia areata usually occurs suddenly in the scalp of one to two circular hair loss. In addition to the scalp, it can be seen on beard, eyebrows, pubic hair, etc. In severe cases, hair loss may occur all over the body. The cause is not yet known, but it is thought to be caused by autoimmune mechanisms, and genetic and mental (particularly stress) causes. Although it may heal naturally, it is a good idea to treat it if symptoms persist for more than three months or progress further. The most common treatment is intra-lesional injection of corticosteroids and treatment of immune response.
휴지기 탈모증은 정상 성인의 경우 하루에 50∼100 개 정도의 휴지기 모발의 탈모가 일어나는데 이 정상탈모 이상의 숫자의 탈모가 일어났을 경우이며 잘 조사를 하면 원인을 찾아 낼수 있는 경우가 많다. 원인이 되는 경우를 보면 하기와 같다.In the stage of alopecia areata, 50 to 100 alopecia hair loss occurs in a normal adult. If the number of hair loss is greater than the normal alopecia, a lot of cases can be found. The causes are as follows.
첫째는 약물복용으로, 항응고제, 항우울제, 고혈압 치료제, 위궤양제, 항관절염제, 항경련제, 비타민 A 유도체제(여드름치료제), 피임제 등을 들 수 있는데, 이들 모든 약제가 원인이 되는 것은 아니며, 만약 이들 약제를 사용하는 중 탈모 문제가 생긴다면 같은 효과를 갖는 다른 제제를 사용하도록 한다.The first is drug use, including anticoagulants, antidepressants, antihypertensives, gastric ulcers, anti-arthritis agents, anticonvulsants, vitamin A derivatives (acne treatments), contraceptives, etc. If you are experiencing hair loss problems while using these drugs, try another agent that has the same effect.
둘째는 과도한 다이어트로, 과도한 다이어트에 의한 단백질 부족이나 철분 부족에 의한 빈혈이 있는 경우 탈모가 일어날 수 있다.Second is excessive diet, hair loss can occur if there is anemia due to lack of protein or iron due to excessive diet.
세째는 스트레스나 열병, 심한 감염질환, 만성질환, 큰 수술 등으로 이들 경우는 원인 발생 약 3 개월이내 탈모가 일어날 수 있다.Third, stress or fever, severe infectious diseases, chronic diseases, major surgery, etc. These cases can cause hair loss within about 3 months of the cause.
네째는 갑상선 항진증 내지는 저하증으로 이들의 경우에도 탈모가 일어날 수 있다.Fourth, hyperthyroidism or hypothyroidism can cause hair loss.
위와 같은 경우는 대부분 원인 자극이 없어지면 6 개월 정도 후에는 모발 성장이 회복된다.In most cases, hair growth is restored after about six months if the causative irritation disappears.
성장기 탈모증은 생장기의 모낭이 급성으로 심한 장애를 받아 두발의 80~90% 이상이 급속하게 탈락되는 상태로 악성 종양 치료시 사용하는 화학요법제와 X-선 조사에 의한 것이 많다. 이 경우 원인 물질의 투여를 중단하면 수 주일 이내에 모낭이 회복되므로 이후는 양호하나, 재생되는 모발이 가늘고 성장이 저하된 경우도많이 볼 수 있다.Growing alopecia is a condition in which hair follicles in the growing stage are acutely severely damaged and more than 80% to 90% of the hair falls out rapidly, and chemotherapy and X-ray irradiation are used to treat malignant tumors. In this case, the hair follicle will recover within a few weeks after the administration of the causative agent is good, but the regenerated hair is thin and growth can be seen in many cases.
두피질환은 지루성 두피염, 진균 질환, 경피증, 루프스, 모냥염, 종양, 매독(3 기)등에서 부분적인 탈모를 보일 수 있다. 위의 질병중 지루성 두피염이 가장 흔하며 퇴행기 탈모증과 비슷한 탈모양상을 보인다. 지루성 두피염은 많은 경우 남성형 탈모증과 같이 나타나는 경우가 많은데 이러한 현상은 DHT에 의해 지루샘도 영향을 받기 때문이다.Scalp disease may show partial hair loss in seborrheic scalpitis, fungal disease, scleroderma, lupus, nymphitis, tumor, syphilis (3rd stage). Seborrheic scalp infection is the most common of the above diseases and is similar to that of alopecia areata. Seborrheic scalp infections often occur with androgenetic alopecia because this phenomenon is also affected by seborrheic glands by DHT.
남성형 탈모증은 많은 경우 이마 양 옆에서부터 시작하여 'M-'자 형태로 올라가면서 가마부위의 탈모가 진행되어 결국 '속알머리'는 빠지고 '주변머리'만 남는 형태로 진행된다. 동시에 모발이 탈모와 함께 가늘고, 작고, 힘이 없어지는 현상을 경험하게 되는 것이 보편적인 현상이다.In many cases, androgenetic alopecia starts from the sides of the forehead and goes up to the 'M-' shape, leading to hair loss at the forehead. At the same time, it is a common phenomenon that the hair experiences thinning, smallness and loss of power along with hair loss.
남성형 탈모는 3 가지 요소 즉 나이, 유전요인, DHT의 영향을 받는다.Androgenetic alopecia is affected by three factors: age, genetic factors and DHT.
이러한 요인들이 남성형 탈모를 일으키는 기전을 살펴보면 다음과 같다.The mechanisms by which these factors cause androgenetic alopecia are as follows.
체내의 남성 호르몬(testosterone)은 대사 과정에서 5-환원 효소에 의해 DHT 형태로 전환되는데 이 DHT가 남성형 탈모 유전요인이 있는 모낭에 작용하여 모낭이 점점 위축 되고 결국 소멸되거나 작은 솜털(연모) 형태로 남게 되는 결과를 초래하게 되는 것이다. 그렇기 때문에 5-환원효소를 억제한다면 남성호르몬의 대사과정에서 DHT가 형성되지 않으나 남성호르몬은 정상적으로 유지되므로 남성 성징은 유지하되 탈모는 방지 할 수 있는 길이 있게 된다.Testosterone in the body is converted to the DHT form by a 5-reduction enzyme during metabolism, which acts on the hair follicles with a male hair loss genetic factor, causing the hair follicles to contract and eventually die off or form a small downy hair. It will result in the remaining. Therefore, if 5-reductase is inhibited, DHT is not formed during the metabolism of male hormones, but male hormones are normally maintained, so male sexual characteristics are maintained but hair loss is prevented.
이 원리를 이용하면 남성형탈모증을 예방할 수 있는 이론적 근거가 성립될 수 있다.Using this principle, the rationale for preventing male alopecia can be established.
위의 이론적 근거로 만들어져 최근에 미국 제약회사인 머크(Merck)사에서 시판이 시작된 약이 프로페시아(Propecia)라는 약이다. 이 복용약은 임상 연구 결과 86 % 정도의 탈모 방지효과와 복용한 군의 66 %정도에서 발모 현상을 보였다고 보고되어 있으며, 미국에서는 올해 1월부터 시판되기 시작했다.Propecia is a drug that is based on the above theory and has recently been marketed by US drug company Merck. The drug has been reported to have prevented hair loss by 86% and hair growth in 66% of the groups taken.
그러나 프로페시아의 단점은But the disadvantage of Propecia
a) 지속적인 복용을 해야 하고,a) take a continuous dose,
b) 비교적 비싼 편이고,b) relatively expensive
c) 미미하나마 성욕감퇴, 발기부전 등의 부작용이 보고되는 등c) minor side effects such as decreased libido and erectile dysfunction
의 문제점이 있다.There is a problem.
미국 FDA에서 인정하는 또 하나의 탈모 방지제로 미노시딜(Minoxidil)이 있는데, 이것은 바르는 약으로 치료대상이 젊고, 기름기가 많고, 가마부위가 빠지는 경우에는 어느 정도 효과(20∼30%)가 있으나 그 이외 경우에서는 별로 좋은 효과를 보이지 못하고 있다.Another hair loss preventer recognized by the US FDA is Minoxidil, which is a topical drug that has some effectiveness (20-30%) in young, oily, and flaky areas. In other cases, the effect is not very good.
여성의 탈모증은 보통 사람들이 생각하는 것보다 훨씬 많으며, 여성의 2/3 정도에서 일생동안 한번은 경험하고 있다. 여성탈모의 종류에는 다음과 같은 여성형 탈모, 임신에 의한 탈모 등의 것이 있다.Alopecia in women is much higher than normal people think, and about two-thirds of women experience it once in their lifetime. The types of female hair loss include the following types of female hair loss and pregnancy hair loss.
여성형 탈모는 남성형 탈모증과 비슷하게 유전하며 나이가 들수록 점진적인 탈모가 일어나나 남자와는 달리 일정한 형태가 없이 머리 전반적으로 탈모가 일어난다. 일반적으로 25 세에서 30 세부터 나타나면서 모발이 점차적으로 가늘고 짧아지면서 가르마 부위가 엷어지는 것을 느끼면서 알게 된다. 성인여성에서의 탈모의50 %가 이러한 탈모이나 불행하게도 확실한 치료법은 없으며 탈모가 영구적이며 유전소인을 보인다.Female alopecia is similar to male alopecia, and hair loss occurs gradually with age, but unlike men, hair loss occurs in general without any form. It usually occurs from 25 to 30 years old, and the hair grows thinner and shorter, and it is noticed by feeling thinning of the garma area. 50% of hair loss in adult women does not have this hair loss, but unfortunately no cure, hair loss is permanent and genetic.
임신에 의한 탈모는 임신 도중이나 임신이 끝난 6 개월 정도에서 탈모가 일어날 수 있으며 많은 경우에는 거의 회복 가능하나 영구적인 탈모를 보이는 경우도 있다.Hair loss due to pregnancy can occur during pregnancy or at the end of 6 months, and in many cases it is almost recoverable, but there are some cases of permanent hair loss.
이외의 여성에게 흔한 탈모는 정상 여성의 경우 하루에 50∼100 개 정도의 휴지기 모발의 탈모가 일어나는데 이 정상탈모 이상의 숫자의 탈모가 있을 때 원인을 찾아보면 원인을 알 수 있는 경우가 많은데 원인이 되는 경우를 보면 아래와 같다.Hair loss that is common to other women is about 50 to 100 hair loss a day in normal women. When the number of hair loss is higher than the normal hair loss, looking for the cause can often reveal the cause. The case is as follows.
첫째는 약물복용으로, 항응고제, 항우울제, 고혈압 치료제, 위궤양제, 항관절염제, 항경련제, 비타민 A유도체제(여드름치료제), 피임제 등을 들 수 있는데, 이들 모든 약제가 원인이 되는 것은 아니며, 만약 이들 약제를 사용하는 중 탈모 문제가 생긴다면 약물복용에 의한 탈모가 조장될 수 있다.The first is medications, which include anticoagulants, antidepressants, antihypertensive drugs, gastric ulcers, antiarthritis agents, anticonvulsants, vitamin A derivatives (acne medications), contraceptives, etc. If hair loss problems occur while using these drugs, hair loss may be encouraged.
둘째는 과도한 다이어트로, 단백질 부족이나 철분 부족에 의한 빈혈이 있는 경우 탈모가 일어날 수 있다.Second is excessive diet, hair loss can occur if there is anemia due to lack of protein or iron deficiency.
세째는 스트레스나 열병, 심한 감염질환, 만성질환, 큰 수술 등의 경우로, 원인 발생 약 3 개월이내 탈모가 일어날 수 있다.Third is the case of stress or fever, severe infectious diseases, chronic diseases, major surgery, hair loss can occur within about three months of the cause.
네째는 갑상선 항진증 내지는 저하증인 경우에 탈모가 일어날 수 있다.Fourth, hair loss may occur in hyperthyroidism or hypothyroidism.
위와 같은 경우는 대부분 원인 자극이 없어지면 6 개월 정도 후에는 모발 성장이 회복된다.In most cases, hair growth is restored after about six months if the causative irritation disappears.
본 발명은 상기 종래 기술의 문제점을 고려하여 체내의 5-환원 효소를 억제하여 남성 호르몬의 대사 과정에서 DHT가 형성되지 않도록 하고, 인체의 상피조직의 기능 수행에 있어서 세포 재생으로 머리카락의 신진 대사 작용을 도와주도록 하여 남성형 탈모증 치료에 사용될 수 있는 모발 성장 조성물을 제공하는 것을 목적으로 한다.In consideration of the problems of the prior art, the present invention inhibits 5-reducing enzymes in the body so that DHT is not formed in the metabolic process of androgen hormones, and metabolism of hair by cell regeneration in the function of epithelial tissues It is an object of the present invention to provide a hair growth composition that can be used to treat androgenetic alopecia.
본 발명의 다른 목적은 보다 근본적으로 모발 성장 및 촉진 효과가 있는 모발 성장 조성물을 제공하는 것이다.Another object of the present invention is to provide a hair growth composition which is more fundamentally hair growth and promoting effect.
[과제를 해결하기 위한 수단][Means for solving the problem]
본 발명은 상기 목적을 달성하기 위하여,The present invention to achieve the above object,
a) 참깨꽃 추출물; 및a) sesame flower extract; And
b) 트레티노인(레티노익 산)b) tretinoin (retinoic acid)
을 포함하는 모발 성장 조성물을 제공한다.It provides a hair growth composition comprising a.
상기 참깨꽃 추출물은 참깨꽃 100 중량부를 메탄올 농도 30 내지 100 중량%의 메탄올 수용액 500 내지 1000 중량부의 용매로 추출하여 제조되는 추출물이 바람직하다.The sesame flower extract is preferably an extract prepared by extracting 100 parts by weight of sesame flowers with 500 to 1000 parts by weight of a methanol solution of 30 to 100% by weight methanol.
[작 용][Action]
이하에서 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 상기 참깨 꽃 추출물과 트레티노인의 사용은 단독으로사용할 때나타나지 않던 모발 성장 상승 효과에 기인한 것이다.In the present invention, the use of the sesame flower extract and tretinoin is due to the hair growth synergistic effect that did not appear when used alone.
또한 인체 대사에 도움을 주는 각종 비타민 및 비타민 전구체를 추가적으로 포함시켜 상기 상승 효과를 나타내는 조성물의 모발 성장 기능을 보다 촉진시킬 수 있다.In addition, by including a variety of vitamins and vitamin precursors to aid in human metabolism can further promote the hair growth function of the composition exhibiting the synergistic effect.
상기 a)의 참깨 꽃 추출물은 체내의 5-환원효소를 억제하여 남성호르몬의 대사과정에서 DHT가 형성되지 않도록 하기 위하여 참깨 중에서 꽃부분만을 채집하여 유효 성분을 추출한 것이다. 상기 조성물 내의 함유량은 0.1 내지 10 중량%가 바람직하며, 0.1 중량% 이하의 함유는 모발 성장 효과가 낮으며, 10 중량% 이상의 함유는 함유량 만큼의 효과가 없다.Sesame flower extract of a) is to extract the active ingredient by collecting only the flower part of the sesame in order to suppress the 5-reductase in the body so that DHT is not formed in the metabolic process of male hormone. The content in the composition is preferably 0.1 to 10% by weight, the content of 0.1% by weight or less is low hair growth effect, the content of 10% by weight or more is not as effective as the content.
상기 b)의 트레티노인은 레티노익산(retinoic acid)라고도 하며, 인체의 상피조직의 기능수행에 필요한 비타민 A로서 세포를 재생함으로서 머리카락의 신진대사 작용을 도와주는 역할을 한다. 트레티노인의 함유량은 0.01 내지 2 중량%가 바람직하다. 0.01 중량% 이하의 함유는 모발 성장 효과가 낮으며, 2 중량% 이상의 함유는 함유량 만큼의 효과가 없다. 특히 상기 b)의 트레티노인과 c)의 비타민 또는 비타민 전구체의 조성물 내 함유량은 그 합으로 0.1 내지 10 중량%에서 효과적이며, 이 범위를 벗어나는 것은 발모 상승 효과와 촉진 효과가 없다.The tretinoin of b) is also called retinoic acid (retinoic acid), and plays a role in helping the hair metabolism by regenerating cells as vitamin A necessary for the function of epithelial tissues of the human body. The content of tretinoin is preferably 0.01 to 2% by weight. The content of 0.01 wt% or less has a low hair growth effect, and the content of 2 wt% or more is not as effective as the content. In particular, the content in the composition of the tretinoin of b) and the vitamin or vitamin precursor of c) is effective at a total of 0.1 to 10% by weight, and beyond this range there is no hair growth synergistic effect and promoting effect.
상기 상승 효과를 갖는 참깨 꽃 추출물과 트레티노인을 포함하는 조성물에 더욱 포함될 수 있는 각종 비타민 및 비타민 전구체 성분들은 비타민 B1, 비타민 B2, 비타민 B6, 비타민 C, 비타민 D, 비타민 E, 니코틴산, 판토텐산, 비오틴 또는 엽산 등이며, 이들은 1 종 이상 선택되어 사용될 수 있다.Various vitamin and vitamin precursor components which may be further included in the composition comprising the sesame flower extract and tretinoin having the synergistic effect are vitamin B1, vitamin B2, vitamin B6, vitamin C, vitamin D, vitamin E, nicotinic acid, pantothenic acid, biotin or Folic acid and the like, and these may be used by selecting one or more kinds.
비타민 B1은 세포의 성장을 도와주며, 이 비타민 B1이 적절히 보급됨으로써 우선 세포의 성장이 정상적으로 이루어진다.Vitamin B1 helps the cells grow, and the proper growth of the vitamin B1 first, the cells grow normally.
비타민 B2는 리보플라빈(Riboflavin)이라고도 하며, 이것은 사람 몸의 부드러운 조직의 신진대사에 매우 중요한 역할을 한다. 조직의 일부에서 다른 부근의 산소를 치환하는 역할도 하면 그밖에 전분과 당분의 동화작용과 신진대사의 기능도 돕는다. 여러 가지 과학적 연구에 의하면 비타민 B2를 주지 않으면 윤기가 없어지고 매끈한 털이 상해 거칠어지면 털이 새로 생겨나는 주기가 바뀌고 탈모가 시작되는 것으로 보고되고 있다.Vitamin B2 is also called Riboflavin, which plays an important role in the metabolism of the soft tissues of the human body. In addition to the role of replacing the oxygen in other parts of the tissue also helps the assimilation and metabolism of starch and sugar. Several scientific studies have reported that vitamin B2 does not give luster and smooth hair injuries change the cycle of new hair growth and start hair loss.
비타민 B6는 피리독신(Pyridoxine)이라고도 하며, 동물실험에서 이것을 결핍시키면 모발의 성장에 지장을 일으킨다. 동시에 영양결핍에 기인하는 비늘상태의 피부염이 생긴다. 이 비타민 B6는 단백질, 지방, 탄수화물울 인체의 활동에 도움을 주는 역할을 한다. 또, 조혈을 돕고, 피부와 신경, 근육의 기능유지 등에 없어서는 안되는 중요한 것이다.Vitamin B6, also known as pyridoxine, is a deficiency in animal testing that can interfere with hair growth. At the same time, scaly dermatitis is caused by malnutrition. This vitamin B6 helps the body work with protein, fat and carbohydrates. In addition, it is important to help hematopoiesis and maintain the function of skin, nerves and muscles.
비타민 C는 본 발명의 항산화물질로서 사용된 것으로, 출혈방지인자라고도 하며 모세혈관으로부터 쉽게 피가 유출되려는 경향을 저지해 준다. 이 비타민의 작용은 비오플라빙의 존재로 인해 한층 더 강화된다. 피부세포를 서로 묶어주고 있는 결체조직을 교원질이라 하며 비타민 C는 이 교원질의 형성에 필요한 비타민이다. 세균성 전염병에 대한 방어력을 갖고 있는 비타민으로 알려져 있으며, 체내에 있어서 히스타민의 과잉생성도 억제하는 작용도 있다. 비타민 C는 외상을 빨리 치료하는 작용도 하고 있으며, 장관으로부터 철분을 흡수하는 것을 도와준다.Vitamin C has been used as an antioxidant of the present invention, also known as anti-bleeding factor and inhibits the tendency for blood to easily leak out of capillaries. The action of this vitamin is further enhanced by the presence of bioflaving. The connective tissue that binds the skin cells together is called collagen. Vitamin C is a vitamin necessary for the formation of collagen. It is known as a vitamin that has protection against bacterial infectious diseases, and also has a function of inhibiting the overproduction of histamine in the body. Vitamin C is also a quick way to heal trauma, helping to absorb iron from the intestines.
비타민 D는 체내의 칼슘의 밸런스를 유지하며 인(燐)의 신진대사와 체내 산소의 치환에도 중요한 역할을 할 수 있다.Vitamin D maintains the balance of calcium in the body and may play an important role in the metabolism of phosphorus and the substitution of oxygen in the body.
비타민 E는 근육조직과 전신의 맥관조직에도 불가결한 요소로 작용하며, 이 비타민이 많이 부족하게 되면 적혈구가 아주 저항력이 약해지고 혈액이 엉겨붙어서 혈관이 막힐 수도 있다.Vitamin E also plays an indispensable factor in muscle tissue and vasculature throughout the body, and a lack of this vitamin can cause red blood cells to become very resistant and clogged blood vessels.
니코틴산은 혈액순환 작용을 도우며, 니아신이라는 상품명을 갖고 있고 비타민 B복합체의 하나이다. 이 화학물질은 피부, 간장, 신경 및 혈액순환 조직이 정상적인 기능을 유지하는데 필요로 한다. 또, 전분과 탄수화물의 동화작용에도 필요하다.Nicotinic acid aids in the blood circulation, has the trade name Niacin and is one of the vitamin B complexes. This chemical is necessary for the normal functioning of the skin, liver, nerves and blood circulation tissues. It is also necessary for the assimilation of starch and carbohydrates.
판토텐산은 피부의 건강유지에 필요한 항피부염 인자요소로서의 작용을 가지고 있을 뿐만아니라 부신의 정상적인 기능을 유지하는데 필요로 하는 물질로서 사용하였다.Pantothenic acid was used as a substance necessary to maintain the normal function of the adrenal gland as well as to act as an anti-dermatitis factor factor necessary for maintaining skin health.
비오틴은 세포발육을 자극시키는 작용을 하며, 동물실험에서 이 물질이 결핍되면 모발의 성장이 저해되는 것으로 알려져 왔다.Biotin acts to stimulate cell development, and it has been known in animal experiments that the lack of this material inhibits hair growth.
엽산은 골수와 세포분자를 자극한다든지, 간장의 적당한 활동을 돕는다든지, 지방분의 인체조직에의 이용을 도와주는 것으로 알려져 있다.Folic acid is known to stimulate bone marrow and cell molecules, to help the liver to work properly, and to help the use of fat in human tissues.
본 발명의 또 다른 식물 추출물로, 솔잎 추출물 및 인삼 추출물로 이루어진 군으로부터 1 종 이상 선택되는 식물 추출물을 더욱 포함할 수 있다. 이들을 포함할 경우에는 상기 a)의 참깨 꽃 추출물과 합하여 조성물 내에 0.1 내지 20 중량% 포함되는 것이 바람직하다. 20 중량% 이상의 함유는 그 효과가 함유량 만큼 나타나지 않는다. 상기 솔잎 추출물 또는 인삼 추출물은 각 추출물이 포함하고 있는 각종 성분들이 공지된 대로 생체 활력, 단백질 효소, 항산화 물질 등으로 작용할 수 있으며, 복합 작용에 의해 본 발명의 상기 상승 효과를 나타내는 조성물의 모발 성장 효과를 보다 촉진시킬 수 있는 것으로 추정된다. 이 추출물들은 상기 c)의 비타민 또는 비타민 전구체에 영향받지 않고 사용될 수 있다.As another plant extract of the present invention, it may further include at least one plant extract selected from the group consisting of pine needle extract and ginseng extract. In the case of including them, 0.1 to 20% by weight of the sesame flower extract of a) is preferably included in the composition. The content of 20% by weight or more does not appear as effective as the content. The pine needle extract or ginseng extract may act as a biological vitality, protein enzymes, antioxidants, and the like, as the various components contained in each extract are known, hair growth effect of the composition showing the synergistic effect of the present invention by a complex action It is estimated that can be promoted more. These extracts can be used without being affected by the vitamins or vitamin precursors of c).
이하의 실시예를 통하여 본 발명을 더욱 상세히 설명한다. 단 실시예는 본 발명을 예시하기 위한 것이지 이들 만으로 한정되는 것은 아니다.The present invention will be described in more detail with reference to the following examples. However, the examples are only for illustrating the present invention and are not limited thereto.
[실시예]EXAMPLE
하기 실시예에서 사용된 각 원료 중에서 인삼추출물 및 은행추출물은 'Abb's Herb Company'의 제품이며, 솔잎추출물, 밤민트추출물(Balm Mint Extract) 및 귀리추출물은 'Herbal Resources Inc' 의 제품이며, 폴리비닐 피롤리돈 K-90 및 K-30은 'GAF Co.'의 제품이다.Among the raw materials used in the following examples, ginseng extract and ginkgo extract are products of 'Abb's Herb Company', pine needle extract, balm mint extract and oat extract are products of 'Herbal Resources Inc', polyvinyl Pyrrolidone K-90 and K-30 are products of GAF Co.
실시예 1Example 1
(참깨꽃 추출물 제조 1)(Sesame Flower Extract Preparation 1)
건조시킨 참깨꽃 분말 200 g을 1.2 ℓ 메탄올에 2 주간 담근다.200 g of dried sesame flower powder are soaked in 1.2 L methanol for 2 weeks.
이 혼합물을 3 시간 동안 리플럭스(reflux) 시킨 후 냉각하여 용액을 거르고, 그 나머지는 메탄올 1 ℓ로 2 번 같은 방법으로 재추출하였다. 각 여과액을 500 ㎖ 회전 증발기에서 혼합하고 농축시켰다.The mixture was refluxed for 3 hours and then cooled to filter the solution, and the remainder was reextracted twice in the same way with 1 liter of methanol. Each filtrate was mixed and concentrated in a 500 ml rotary evaporator.
이 농축용액을 증류된 아세톤 2.5 리터에 더하여 형성된 침전물은 아세톤과 분리 정제하였다. 이 침전물을 3 시간 동안 감압 증발한 후 건조기에 보관하였다.수득율은 18 g이었다.This concentrated solution was added to 2.5 liters of distilled acetone, and the precipitate formed was separated and purified with acetone. The precipitate was evaporated under reduced pressure for 3 hours and then stored in a dryer. Yield was 18 g.
실시예 2Example 2
(참깨꽃 추출물 제조 2)(Sesame Flower Extract Preparation 2)
1 kg 분말 참깨꽃을 6 ℓ 메탄올에 2 주간 담근다.Soak 1 kg powdered sesame seeds in 6 L methanol for 2 weeks.
이 혼합물을 8 시간 동안 리플럭스 시킨 후 냉각하여 용액을 거르고, 그 나머지는 메탄올 1 ℓ로 2 번 같은 방법으로 재추출하였다. 각 여과액을 500 ㎖ 회전 증발기에서 혼합하고 농축시켰다.The mixture was refluxed for 8 hours and then cooled to filter the solution, the remainder was reextracted twice in the same way with 1 liter of methanol. Each filtrate was mixed and concentrated in a 500 ml rotary evaporator.
이 농축용액을 증류된 2.5 리터 에틸에테르에 더하여 형성된 침전물은 에틸에테르와 분리 정제하였다. 이 침전물을 3 시간 동안 감압 증발한 후 건조하였다. 상기 에틸에테르에서 녹지 않은 물질은 3 ℓ 물에 다시 녹이고, 그 침전물을 3 일 후에 감압 증발한 후 건조하였다. 두 건조분말을 잘 섞어 건조기에 보관하였다. 수득율은 30 g이었다.This concentrated solution was added to distilled 2.5 liter ethyl ether and the precipitate formed was separated and purified with ethyl ether. This precipitate was evaporated under reduced pressure for 3 hours and then dried. The material which was not dissolved in the ethyl ether was dissolved in 3 L of water again, and the precipitate was evaporated under reduced pressure after 3 days and dried. The two dry powders were mixed well and stored in a dryer. Yield 30 g.
실시예 3Example 3
(참깨꽃 추출물 제조 3)(Sesame Flower Extract Preparation 3)
건조시킨 참깨꽃 분말 300 g을 2.2 ℓ 메탄올에 2 주간 담근다.300 g of dried sesame flower powder is soaked in 2.2 L methanol for 2 weeks.
이 혼합물을 4 시간 동안 리플럭스 시킨 후 냉각하여 용액을 암베르라이트(Amberlite) IRN 77 양이온 교환 수지를 이용하여 걸르고, 그 나머지는 메탄올 1 ℓ로 2 번 같은 방법으로 재추출하였다. 각 여과액을 500 ml 회전 증발기에서 혼합하고 농축시켰다.The mixture was refluxed for 4 hours and then cooled to filter the solution using Amberlite IRN 77 cation exchange resin and the remainder was reextracted twice with 1 L of methanol in the same manner. Each filtrate was mixed and concentrated in a 500 ml rotary evaporator.
이 농축용액을 증류된 아세톤 2.5 리터에 더하여 형성된 침전물은 아세톤과분리 정제하였다. 이 침전물을 3 시간동안 감압 증발한 후 건조기에 보관하였다. 수득율은 12 g이었다.This concentrated solution was added to 2.5 liters of distilled acetone and the precipitate formed was separated and purified with acetone. The precipitate was evaporated under reduced pressure for 3 hours and then stored in a drier. Yield was 12 g.
실시예 4Example 4
(로션 제형의 발모 조성물)(Hair growth composition of lotion formulation)
통상적인 로션 제형을 기준으로 상기 실시예 1에서 제조된 참깨꽃 추출물, 트레티노인, 비타민 또는 비타민 전구체로 비오틴, 니코틴산 및 비타민 B1, 식물 추출물로 인삼추출물을 포함하는 하기 표 1의 로션 제형의 발모 조성물을 통상적인 로션 제조 방법으로 혼합하여 제조하였다.Based on the conventional lotion formulation, sesame flower extract prepared in Example 1, tretinoin, vitamin or vitamin precursor biotin, nicotinic acid and vitamin B1, plant extracts containing ginseng extract as a plant extract It was prepared by mixing in a conventional lotion manufacturing method.
실시예 5Example 5
(크림 제형의 발모 조성물)(Regrowth composition of cream formulation)
통상적인 크림 제형을 기준으로 상기 실시예 2에서 제조된 참깨꽃 추출물, 트레티노인, 비타민 또는 비타민 전구체로 비타민 B1, B6(염산피리독신) 및 E, 식물 추출물로 솔잎추출물을 포함하는 하기 표 2의 크림 제형의 발모 조성물을 통상적인 크림 제조 방법으로 혼합하여 제조하였다.Cream formulation of Table 2 comprising sesame flower extract, tretinoin, vitamin or vitamin precursor B1, B6 (pyridoxine hydrochloride) and E as a plant extract, pine needle extract as a plant extract, based on a conventional cream formulation Hair regrowth composition was prepared by mixing in a conventional cream preparation method.
실시예 6Example 6
(에멀전 제형의 발모 조성물)(Hair Regrowth Composition of Emulsion Formulation)
통상적인 에멀젼 제형을 기준으로 상기 실시예 3에서 제조된 참깨꽃 추출물, 트레티노인, 비타민 또는 비타민 전구체로 비오틴, 판토텐산, 비타민 B2(리보플라빈), B6(염산피리독신) 및 E, 식물 추출물로 인삼추출물을 포함하는 하기 표 3의 에멀젼 제형의 발모 조성물을 통상적인 에멀젼 제조 방법으로 혼합하여 제조하였다.Biotin, Pantothenic Acid, Vitamin B2 (Riboflavin), B6 (Pyridoxine) and E, Ginseng Extract as Plant Extract The hair growth composition of the emulsion formulation of Table 3 was prepared by mixing in a conventional emulsion preparation method.
실시예 7Example 7
(에센스 제형의 발모 조성물)(Hair Regrowth Composition of Essence Formulation)
통상적인 에센스 제형을 기준으로 상기 실시예 1에서 제조된 참깨꽃 추출물,트레티노인, 비타민 또는 비타민 전구체로 B2, 식물 추출물로 솔잎추출물을 포함하는 하기 표 4의 에센스 제형의 발모 조성물을 통상적인 에센스 제조 방법으로 혼합하여 제조하였다.Sesame flower extract prepared in Example 1 based on a conventional essence formulation, tretinoin, B2 as a vitamin or vitamin precursor, a hair extract composition of the essence formulation of the following Table 4 containing a pine needle extract as a plant extract It was prepared by mixing.
실시예 8Example 8
(스프레이 제형의 발모 조성물)(Hair Regrowth Composition of Spray Formulation)
통상적인 스프레이 제형을 기준으로 상기 실시예 1에서 제조된 참깨꽃 추출물, 트레티노인, 식물 추출물로 인삼추출물을 포함하는 하기 표 5의 스프레이 제형의 발모 조성물을 통상적인 스프레이 제조 방법으로 혼합하여 제조하였다.Based on the conventional spray formulation, the sesame flower extract prepared in Example 1, tretinoin, and plant extract were prepared by mixing the hair growth composition of the spray formulation of Table 5 including the ginseng extract by the conventional spray preparation method.
실시예 9Example 9
(임상실험)(Clinical experiment)
지금까지 한번도 치료를 받지 않은 80 명의 남성 대머리 환자를 대상으로 하기와 같은 임상 실험을 실시하였다.The following clinical trials were conducted in 80 male bald patients who have never been treated before.
심각한 질병으로 고생하는 이들과 호르몬이나 발모제의 치료를 받았던 사람들은 이 실험에서 제외하고 이들 환자들을 2 개의 군으로 나누고 60 명은 치료군으로 20 명의 환자들은 대조군으로 하였으며, 이 두 군의 일반적 자료를 표 6와 같이 비교해 보면 통계적으로는 특별한 차이를 보이지 않았다.Those who suffered from serious illness and those who were treated with hormones or hair regrowth were divided into two groups, 60 were treated and 20 were treated as controls, except for this experiment. In comparison, there was no statistical difference.
상기 치료군에는 실시예 4의 로션타입 발모 조성물을 10 주 동안 하루에 1∼2 번 탈모부위에 발라주고, 상기 대조군에는 실시예 4의 로션타입 발모 조성물에서 식물추출물과 비타민을 제외한 크림 조성물을 10 주 동안 하루에 1∼2 번 탈모부위에 발라주었다.In the treatment group, the lotion type hair growth composition of Example 4 was applied to the bald area once or twice a day for 10 weeks, and the control group included the cream composition except the plant extract and the vitamin in the lotion type hair growth composition of Example 4 for 10 weeks. While applied to the hair loss site 1-2 times a day.
10 주 후의 각 군의 발모 효과를 표 7에 나타내었다.The hair growth effect of each group after 10 weeks is shown in Table 7.
상기 표 7에서 나타낸 모발의 발모 효과는 다음의 3 단계로 표현하였다.The hair growth effect of the hair shown in Table 7 was expressed in the following three stages.
무변화 : 모발이 다시 자라는 게 거의 없음.No change: almost no hair grows again.
보통 : 전체적으로 조금씩 자라나는 게 보임.Normal: It seems to grow little by little.
우수 : 전체적으로 꽉 찬 듯이 다시 자라는 모발을 볼 수 있음.Excellent: You can see the hair growing back as if full.
상기 결과에서 보듯이 80 명의 환자들에 대한 임상실험은 본 발명 발모제 조성물이 남성에게 모발성장을 증가시키는 것으로 나타났다.As shown in the above results, clinical trials of 80 patients showed that the hair regrowth composition of the present invention increased hair growth in men.
본 발명의 조성물은 체내의 5-환원 효소를 억제하여 남성 호르몬의 대사 과정에서 DHT가 형성되지 않도록 하고, 인체의 상피조직의 기능 수행에 있어서 세포 재생으로 머리카락의 신진 대사 작용을 도와주도록 하여 남성형 탈모증 치료에 사용될 수 있다.The composition of the present invention inhibits 5-reducing enzymes in the body so that DHT is not formed in the metabolic process of testosterone and helps the hair metabolism by cell regeneration in the functioning of epithelial tissues of the human body. It can be used for treatment.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990029648A KR100308491B1 (en) | 1999-07-21 | 1999-07-21 | Composition for growthing hair |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990029648A KR100308491B1 (en) | 1999-07-21 | 1999-07-21 | Composition for growthing hair |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010010655A KR20010010655A (en) | 2001-02-15 |
KR100308491B1 true KR100308491B1 (en) | 2001-09-26 |
Family
ID=19603495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019990029648A KR100308491B1 (en) | 1999-07-21 | 1999-07-21 | Composition for growthing hair |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100308491B1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100645090B1 (en) * | 2005-01-13 | 2006-11-23 | (주)트리코진 | Composition for stimulating growth of dermal papilla cells and promoting hair follicle growth comprising Vitamin C Derivatives |
BR102012006715A2 (en) * | 2012-03-26 | 2018-09-18 | Personal Laces Farm De Manipulacao Para Cosmeticos Ltda Me | scalp and its release |
CN104189032A (en) * | 2014-08-06 | 2014-12-10 | 张秀贞 | Medicinal liquor for hair growth and preparation method of medicinal liquor for hair growth |
-
1999
- 1999-07-21 KR KR1019990029648A patent/KR100308491B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20010010655A (en) | 2001-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100992565B1 (en) | Topical preparations for hair growth | |
US8652543B2 (en) | Cosmetic and/or pharmaceutical compositions and their applications | |
MXPA00001000A (en) | A hair lotion with improved properties in its hair protecting action and prevention of hair loss, and the reduction of external effects of androgenic alopecia and resulting hair loss. | |
KR101550179B1 (en) | a composite for preventing depilation and growing hair | |
JP3321712B2 (en) | Topical hair restorer containing pine extract | |
US20040214750A1 (en) | Medicaments for healing skin conditions in humans | |
KR101661245B1 (en) | Hair loss preventing, skin and scalp protecting herbal cosmetic composition containing extracts of saxifrage, coptis, houttuynia, ginseng, peony root, paeonia suffruticosa, yeast and pleuropterus multiflorus, and its manufacturing method | |
KR20110045341A (en) | Improvement composite of scalp and hair be contain yeast, gold, propolis, ginseng, purslane, clove, pleuropterus multiflorus | |
JPS63115807A (en) | Cosmetic | |
KR100308491B1 (en) | Composition for growthing hair | |
KR20210065968A (en) | Iron Chelating Compounds for Treating Aesthetic Skin Conditions | |
JPH0853327A (en) | Hair tonic composed of allantoin or its derivative | |
JPH03112912A (en) | Cosmetic composition | |
JP7135106B2 (en) | Scalp and hair composition | |
US11045510B2 (en) | Combination of aqueous extracts of watercress and nasturtium and ATP for use in the treatment of alopecia | |
JP5414137B2 (en) | Hyaluronidase activity inhibitor | |
KR20090022224A (en) | Cosmetic composition for scalp protection and trichogenousness | |
JP3357746B2 (en) | Hair restorer | |
JPH11302131A (en) | Cosmetic for scalp and hair | |
JPH11302133A (en) | Cosmetic for scalp and hair | |
CN112915176B (en) | Alpinia katsumadai composition for preventing and treating alopecia | |
KR100704754B1 (en) | Galenic composition for promoting hair-resotoration | |
KR20090059230A (en) | Cosmetic composition for anti-alopecia and trichogenousness | |
US20240189201A1 (en) | Hair serum and supplement | |
KR20100111640A (en) | Manufacturing method of cosmetic composition for trichogenousness or anti-alopecia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120830 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20130705 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20140801 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20150724 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20160722 Year of fee payment: 16 |
|
LAPS | Lapse due to unpaid annual fee |